Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11290576 | PMC |
| http://dx.doi.org/10.3324/haematol.2024.285845 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Different Role of PET-CT Evaluation in Newly Diagnosed Follicular Lymphoma Upon Rituximab-Based Chemotherapy and Chemo-Free Immunotherapy.
Hematol Oncol
January 2025
State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Newly diagnosed follicular lymphoma (FL) patients usually received first-line rituximab-based immunochemotherapy (R-chemo). Recently, rituximab plus lenalidomide (R2) emerged as an alternative chemo-free immunotherapy. We performed a comparative analysis of positron emission tomography/computed tomography (PET/CT) in FL undergoing R-chemo or R2.
View Article and Find Full Text PDF[Different Prophylaxis Strategies for Central Nervous System Recurrence of Diffuse Large B-Cell Lymphoma].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
October 2024
Department of Pharmacy, Shengli Clinical Medical College of Fujian Medical University, Fujian Provincial Hospital, Fuzhou 350001, Fujian Province, China.
Article Synopsis
- The study aimed to compare the effects of high-dose methotrexate (HD-MTX) and lenalidomide for preventing central nervous system (CNS) relapses in patients with diffuse large B-cell lymphoma (DLBCL) who are at high risk for CNS recurrence.
- A retrospective analysis included 200 DLBCL patients, assessing CNS relapse-free survival (CRFS), progression-free survival (PFS), and overall survival (OS) rates among those treated with either HD-MTX or lenalidomide, with no significant survival differences found overall.
- Subgroup analysis revealed that while the CRFS rates were similar for high-risk patients in both groups, the lenalidom
Rising Prevalence of Low-Frequency Gene Mutations after Second HDCT in Multiple Myeloma.
Curr Issues Mol Biol
July 2024
Department of Medical Oncology, University Hospital Bern, 3010 Bern, Switzerland.
Multiple myeloma (MM) first-line treatment algorithms include immuno-chemotherapy (ICT) induction, high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) consolidation, followed by lenalidomide maintenance. After these initial therapies, most patients suffer a disease relapse and require subsequent treatment lines including ICT, additional HDCT and ASCT, or novel immunotherapies. The presence of somatic mutations in peripheral blood cells has been associated with adverse outcomes in a variety of hematological malignancies.
View Article and Find Full Text PDFTranscriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
Nat Commun
August 2024
Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA.
Article Synopsis
- Immunochemotherapy is currently the primary treatment for newly diagnosed diffuse large B-cell lymphoma (ndDLBCL), but it's ineffective for some patients, prompting research into better prognostic methods.
- By analyzing transcriptomic data from a large group of patients, researchers identified seven distinct clusters of ndDLBCL, with one specific cluster (A7) linked to poorer outcomes due to characteristics like low immune cell presence and high MYC expression.
- The study also explores how certain drugs, like lenalidomide, may improve treatment for the high-risk A7 cluster by enhancing T-cell movement into tumors and the expression of key tumor markers, while identifying TCF4 as a crucial factor in MYC biology for this group.
to: Immunochemotherapy plus lenalidomide for high-risk mantle cell lymphoma with measurable residual disease evaluation.
Haematologica
August 2024
Lymphoma Service, Division of Hematologic Malignancies, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!